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Background: Resource utilisation and direct costs associated with glaucoma progression in Europe are
unknown. As population progressively ages, the economic impact of the disease will increase.
Methods: From a total of 1655 consecutive cases, the records of 194 patients were selected and stratified
by disease severity. Record selection was based on diagnoses of primary open angle glaucoma, glaucoma
suspect, ocular hypertension, or normal tension glaucoma; 5 years minimum follow up were required.
Glaucoma severity was assessed using a six stage glaucoma staging system based on static threshold
visual field parameters. Resource utilisation data were abstracted from the charts and unit costs were
applied to estimate direct costs to the payer. Resource utilisation and estimated direct cost of treatment, per
person year, were calculated.
Results: A statistically significant increasing linear trend (p = 0.018) in direct cost as disease severity
worsened was demonstrated. The direct cost of treatment increased by an estimated J86 for each
incremental step ranging from J455 per person year for stage 0 to J969 per person year for stage 4
disease. Medication costs ranged from 42% to 56% of total direct cost for all stages of disease.
Conclusions: These results demonstrate for the first time in Europe that resource utilisation and direct
medical costs of glaucoma management increase with worsening disease severity. Based on these
findings, managing glaucoma and effectively delaying disease progression would be expected to
significantly reduce the economic burden of this disease. These data are relevant to general practitioners
and healthcare administrators who have a direct influence on the distribution of resources.
G
laucoma is a leading cause of blindness worldwide
and is the second most frequent cause of legal
blindness in industrialised countries.1–8 In glaucoma
the optic nerve is progressively damaged causing defects in
the visual field, usually asymptomatic until the central vision
is affected.9 10 The goal of glaucoma management is to
preserve the patient is quality of life.9 11 The only treatment
option proved to prevent the loss of vision is to lower the
intraocular pressure to a level deemed safe for the eye.12 The
recommended steps for lowering the intraocular pressure in
primary open angle glaucoma (POAG) are topical medica-
tions first, followed by laser trabeculoplasty and, lastly,
incisional surgery.9 The global prevalence of glaucoma was
estimated at 67 million people in 2001; a projection of these
data to European countries estimates 9.25 million glaucoma
patients in Europe, of which 4.6 to 6.9 million were
undiagnosed and untreated.13
In 2000, the prevalence of glaucoma in the United
Kingdom was estimated to be as high as 3.3% in people over
40 years of age and up to 5% in those aged 80 and over.14 In
Italy, approximately 50 000 people are visually handicapped
by glaucoma, while an estimated 540 000 people over
40 years had glaucoma, half of which are undiagnosed.15 In
Germany, glaucoma was reported as the third leading cause
of blindness (1.6/100 000); an estimated one fifth of all cases
of legal blindness in people aged 75 and older were the result
of glaucoma (22.8/100 000).16 Approximately 500 000 patients
in France are followed and treated for POAG with a similar
number of cases undiagnosed.17 18
Glaucoma costs the US healthcare system an estimated
$2.5 billion annually: $1.9 billion in direct costs and $0.6
billion in indirect costs.18 The annual direct medical cost of
treating newly diagnosed open angle glaucoma was esti-
mated at $1055 based on a retrospective analysis conducted
in 1998.19 A cost effectiveness analysis estimated average
annual cost for standard therapy in treatment of glaucoma at
FFr2389 (US$398) per patient in France and £380 (US$627)
per patient in the United Kingdom (US$1=FFr6.60; £0.61).20
Several international retrospective chart reviews have
considered the economic burden of the management of
glaucoma, particularly in the first 2 years after diagnosis.18 19
However, few data exist on the resource consumption as a
function of disease severity and, in particular, of treating
advanced stage disease. A study in Canada showed an
increase in direct costs with more severe damage.21 The aims
of this study were to estimate resource utilisation and direct
medical costs associated with the long term management of
glaucoma of different severities in five European countries
(Austria, France, Germany, Italy, and the United Kingdom),
and to test the hypothesis that resource consumption and
direct costs increase as disease severity worsens.
Abbreviations: CLV, corrected loss variance; CPSD, corrected pattern
standard deviation; GSS, glaucoma staging system; IOP, intraocular
pressure; LV, loss variance; MD, mean defect or mean deviation; POAG,
primary open angle glaucoma; PSD, pattern standard deviation
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PATIENTS AND METHODS
Recruitment and sampling
Sites within the participating countries were recruited based
on the availability of patient records spanning a minimum of
5 years between 1995 and 2003. At each site, approval was
obtained from the ethics committee and/or institutional
review board according to local and national policy.
Patients with diagnoses of POAG (ICD-9 code 365.11),
normal tension glaucoma (ICD-9 code 365.12), ocular
hypertension (ICD-9 code 365.04), or glaucoma suspect
(ICD-9 code 365.0), and at least 5 years of continuous follow
up were selected. Patients with concomitant ocular diseases
likely to affect glaucoma treatment related resource con-
sumption and those enrolled at any time in a clinical trial
were excluded.
A glaucoma staging system (GSS) based on visual field
defects was used to classify patients into categories of
severity. A number of existing GSSs were reviewed.21–29 The
Bascom Palmer (Hodapp-Anderson-Parrish) GSS was chosen
for use in this study as it allows structured severity stage
assignment based on visual field parameters, in a manner
that is easily applicable to a retrospective chart review since it
is based on the most widely available automated threshold
testing technology.25 Patients were allocated to six disease
severity categories adopting this GSS (table 1).30
Chart review
Data collected included patient demographics, glaucoma risk
factors, number of ophthalmologist visits, number and type
of glaucoma medications and surgeries, and visual field
results. All clinical tests documented in the charts were
recorded. Both essential examinations, such as intraocular
pressure (IOP) assessments, optic nerve assessments, retinal
or macular examinations, slit lamp examinations, goniosco-
pies, as well as more specialised tests, such as diurnal curves
of IOP measurements, retinal nerve fibre thickness assess-
ments, and optic disc photographs were considered.
‘‘Study entry’’ was defined by the date on which the first
binocular set of static threshold visual fields was documented
in the chart at least 5 years previously. This set of visual fields
was used to assign a baseline stage based on the GSS. For
stage 5 (end stage) patients, visual acuity at study entry was
also used to determine their initial staging. The cases were
staged and selected for chart abstraction until a minimum of
two per stage (stages 0 to 5) was identified for each site (that
is, a minimum of 12 charts per site). Patients were staged on
the basis of the worse eye visual field score. A total of 1655
consecutive charts were reviewed to obtain the study sample
of 194 charts.
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For each country health economists were consulted to
provide publicly available unit costs associated with diag-
nostic tests, surgical procedures, and medication data
abstracted from the charts.31–34 The annual direct cost of
treatment per person year, including a breakdown of costs
attributed to office visits, diagnostic procedures, glaucoma
surgeries, cataract extractions, and glaucoma medications
was calculated per stage of disease. For all patients, all direct
costs were assumed to be ophthalmology costs and included
costs associated with ophthalmologist visits, glaucoma
surgeries, Hemifield visual field testing, medications, and
other glaucoma services, such as gonioscopies, optic disc
photographs, nerve fibre thickness analysis, and IOP diurnal
testing. For patients in stage 5, non-physician costs, as low
vision care/vision rehabilitation services, were not included
since they were not recorded on the hospital charts.
Based on the number of drops per bottle, a 5 ml bottle of
an ocular medication prescribed twice daily or its equivalent
(for example, a 2.5 ml bottle of a medication prescribed once
daily) was assumed to represent a 1 month supply for any
given patient. Data on medication usage were collected at
every visit and patients were assumed to adhere fully to
medication regimens unless otherwise noted in the chart.
Statistical analyses
To calculate the number of resources consumed per person
time by stage, the total number of each resource consumed in
each stage of glaucoma was added and then divided by the
total of all patients’ follow up time in that stage. As visits
occurred frequently and visual fields were assessed regularly,
the number of these resources consumed per person year was
calculated. Surgical procedures were performed with less
frequency, and therefore reported per 100 person years.
Conversely, as there was extensive medication use in this
population, with frequent prescription changes, these costs
were calculated on a daily basis. The person time values were
multiplied by unit costs for each country to calculate the
direct cost by stage over time (for example, J/person year).
RESULTS
Demographics
From the 1665 consecutive cases examined, a total of 194
charts (47.9% female) met the review criteria. An equal
number of patients from each stage were selected (mean
32.5, median 32, range 31–34); the demographics are
presented in figure 1. The mean age of the study sample
was 64.7 years (SD 12.1), and was significantly lower
(p(0.01) for stage 0 (57.6 for stage 0, 65.7 for stage 1, 64.1
for stage 2, 66.0 for stage 3, 67.5 years for stage 4, and 67.7 for
stage 5).
Resource utilisation
The use of resources increased with the worsening of disease
(table 2). The number of ophthalmologist visits per person
year increased with each worsened stage with a significant
linear trend (p=0.001). The number of visual fields
performed increased from stage 0 to stage 3 and decreased
from stage 4 to 5. Laser trabeculoplasty was most common in
early stages (stage 2 with 8.1 surgeries per 100 person years),
while trabeculectomy was most common in more advanced
stages (stage 4 with 8.9 per 100 person years). A statistically
significant increasing linear trend (p=0.008) was observed
in the number of glaucoma medications per person month
used from stage 0 to stage 5. As expected, cataract extractions
did not show any specific trend.
Table 2 Number of resources utilised per person time
Resource (per person time unit)
Disease stage (n)
0 (33) 1 (32) 2 (34) 3 (33) 4 (31) 5 (31)
Office visits (per 1 person year) 2.9 3.0 3.1 3.4 3.7 3.7
Visual fields (per 1 person year) 1.2 1.4 1.5 1.7 1.6 1.0
Trabeculoplasties (per 100 person years) 2.6 3.5 8.1 5.2 5.3 4.4
Trabeculectomies (per 100 person years) 0.0 2.5 2.7 3.1 8.9 4.4
Glaucoma medications (per 1 person month) 1.1 1.2 1.7 1.5 1.8 2.4
Table 3 Direct healthcare cost of glaucoma treatment per person year by stage
Disease
stage France Germany* Italy United Kingdom
0 J414 J918 J153 J457
1 J718 J814 J386 J595
2 J820 J986 J421 J670
3 J601 J928 J669 J533
4 J1002 J1194 J791 J829
5 J812 J952 J712 J1065
*Includes data of 12 charts from Austria.
€1000
€800
€400
€600
€200
€0
Stage 5
C
os
t
Stage 4Stage 3Stage 2Stage 1Stage 0
€886
€969
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€656
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Office visits
Glaucoma exams
Visual fields
Glaucoma surgeries
Cataract extractions
Medications
Figure 2 Direct cost of glaucoma treatment in Europe per person year
by stage.
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Direct costs
Table 3 depicts the annual direct cost of glaucoma treatment
by stage. A statistically significant linear trend (p=0.018),
showing an increase in direct cost as disease severity
worsened, is demonstrated. Direct ophthalmology costs were
estimated at J455 per person year for stage 0 patients and
increased as disease severity worsened to an estimated J969
per person year for patients with stage 4.
Annual direct costs of treatment were also calculated for
each participating country, stratified by stage of disease,
based on the corresponding utilisation of resources (table 2).
With the exception of Germany, an increase in direct cost
from stage 0 to stage 4 was observed in all countries, and was
significant for Italy (p=0.026) and the United Kingdom
(p=0.037). Stage 5 costs were lower than stage 4 costs,
except in the United Kingdom. A statistically significant
increasing trend (p=0.037) in direct cost was observed in
Italy from stage 0 to stage 5, where medications and
glaucoma surgery accounted for the majority of cost. The
resource consumption peaked for stage 4 with J791 per
person year and slightly decreased for stage 5 patients. A
statistically significant increasing trend (p=0.026) in direct
cost was observed in the United Kingdom from stage 0 to
stage 5. Medications and outpatient clinic visits accounted for
the majority of these costs (fig 2).
DISCUSSION
In examining medical resource consumption associated with
a chronic, potentially blinding disease, such as glaucoma, one
may postulate that as disease severity worsens, greater
medical effort will be prompted by physicians’ goals to slow
disease progression as well as by increased patient concern.
In particular, being glaucoma asymptomatic in the early
phases resulting most often in delayed diagnosis, a reactively
increased medical vigilance is afterwards likely as disease
progresses. This study supports this hypothesis in chronic
glaucoma patients, showing that resource utilisation and
direct medical treatment costs increase as disease severity
worsens.
Patients with end stage disease, stage 5 for our study,
typically have failed to adequately respond to conventional
ocular hypotensive medications and may have already
undertaken numerous surgical procedures with suboptimal
results.
Direct ophthalmology resource utilisation, including phy-
sician visits, glaucoma surgeries, and medications, was lower
for patients with stage 5 compared to stage 4 in all countries
except the United Kingdom. This may be explained by the
fact that ophthalmologists have less to offer to such severely
visually impaired patients in terms of therapy to preserve
vision, compared with patients with less severe disease.
Moreover, low vision care, vision rehabilitation services, and
non-physician resources where patients with end stage
disease may be referred to for further management were
not calculated as direct medical costs.
When full compliance with medications is assumed,
medication costs represent a minimum of 42% of total direct
cost at any disease stage. Since topical ocular hypotensive
medications are as effective as early surgery in delaying the
rates of progression,35 the majority of physicians are likely to
offer medication therapy before advising surgery. In general,
preventing patients progressing from stage 0 or 1 to stage 4 or
5 will project a decrease between 30–50% of the costs.
The overall results from this study appear to be within the
range of similar glaucoma resource utilisation studies,19–21 36 37
but there are methodological limitations. Glaucoma progression
may be measured by ophthalmologists using visual field
examination, optic nerve head clinical assessment, or both.11
Visual field examination is the standard of care to evaluate
disease progression, and for clinicians it represents the driver for
adjusting the management of the patient.9 36–40
Since the study retrospectively collected patient data from
the previous 5–7 years, the number of years a patient may
have been in his/her baseline stage before the study entry
could not be controlled. Patients with at least 5 years of
follow up data may differ from patients who do not seek
persistent care for glaucoma for the same period, thus
creating a potential selection bias. Data on patients in end
stage disease who may have been referred to low vision care
and vision rehabilitation centres were not captured and the
total medical and societal costs associated with end stage
disease were not fully estimated. Examining costs from a
societal perspective, as opposed to a payer perspective, may
have an impact on treatment cost of end stage glaucoma; in
particular, as costs for low vision care and vision rehabilita-
tion centres are likely to be borne by the patient or society,
such resources are inherently excluded from medical costing
methods. The relatively small number of charts reviewed may
limit the generalisability of the results.
Data on ocular hypotensive medication use were collected
at every ophthalmic visit and for cost calculations it was
assumed that patients fully adhered to medication regimens;
this may overestimate real life resource utilisation and costs
associated with medication use. Medication costs are
distributed over periods of months to several years while
surgical costs are incurred at a single point in time and are
represented in the analysis as costs divided over the period
that patients remain categorised within a given stage. For
example, the relatively high unit cost of an incisional surgery
will be divided by the number of years of follow up and may
therefore be reported as a lower yearly cost. This costing
approach still represents the best approximation of actual
surgical costs given sample size and timelines. The possibility
of surgery to control the IOP for years in the majority of
patients is well documented.41 42
Our study demonstrates a significant linear trend in
resource consumption and total direct cost, both increasing
with worsening of disease severity. The direct cost of
treatment increased by an estimated J86 for each incre-
mental increase in stage. The costs ranged from J455 per
person year for early stage (stage 0) to J969 per person year
for late stage (stage 4) disease across Europe; similar trends
were observed across each analysed countries. Health policy
models have been constructed for other conditions, such as
stroke, to allow for investigation of policy issues and
options43; similar analyses in glaucoma are warranted.
According to our results, glaucoma management strategies
aimed at slowing or stopping disease progression, if effective,
would be expected to significantly reduce the health
economic burden of this chronic disease over many years.
Ophthalmologists, general practitioners, and health admin-
istrators now have a European based set of data demonstrating
that managing glaucoma effectively, preventing progression
beyond the early to moderate stages of the disease, will result in
a decrease in direct costs. This should be used to offset the
constraints on resource delivery to manage patients with an
unquestionable diagnosis of progressive glaucoma.
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